Market Movers Today: Omeros Corporation (OMER), AbbVie Inc (ABBV), Darden Restaurants, Inc. (DRI), Odyssey Marine Exploration Inc (OMEX), and More

Omeros Corporation (NASDAQ:OMER) (MarketWatch)
Omeros Corp. OMER, +36.60% shares surged 45% in extremely heavy morning trade Thursday on a new government spending bill that benefits its cataract surgery drug Omidria. Omidria’s “pass-through” status with Medicare, which allows for a higher reimbursement rate, expired late last year, and the drug was expected to be bundled with other cataract surgery supplies, which might have forced Omeros to decrease the price “by up to 90 percent to remain competitive,” said Height analyst Andrea Harris.

AbbVie Inc (NYSE:ABBV) (The Motley Fool)
What happened: After the biotech giant’s disappointing update on an important experimental cancer drug, shares of AbbVie (NYSE:ABBV) fell as much as 12% in early morning trading on Thursday. Shares were down 11% as of 10:35 a.m. EDT. So what: The drug in question is called rovalpituzumab tesirine, which goes by the nickname Rova-T. AbbVie shared a little bit of data from a phase 2 trial today that was studying Rova-T as a third-line treatment for relapsed/refractory small-cell lung cancer.

stock, exchange, trade, ipo, market, london, share, rate, sales, price, new, york, profit, index, broker, chart, rising, falling, street, frankfurt, wall, world, cash, points, display,

lassedesignen/Shutterstock.com

Odyssey Marine Exploration Inc (NASDAQ:OMEX) (Benzinga)
Odyssey Marine Exploration, Inc. shares jumped 150.1 percent to $9.48 after the company disclosed positive Mexico Court Decision nullifying a previous denial of application for Don Diego project.

Darden Restaurants, Inc. (NYSE:DRI) (CNBC)
Darden Restaurants – The parent of Olive Garden and other restaurant chains came in 7 cents a share above estimates, with adjusted quarterly profit of $1.71 per share. It also increased its full-year outlook to a range that comes in mostly above current consensus. The most recent quarter’s revenue, however, did fall below analyst estimates.